Ferguson Wellman Capital Management Inc buys $53,865,835 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Ferguson Wellman Capital Management Inc scooped up 68,290 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 949,345 shares of Merck & Co. which is valued at $53,865,835.Merck & Co. makes up approximately 2.24% of Ferguson Wellman Capital Management Inc’s portfolio.

Merck & Co. opened for trading at $56.69 and hit $57.03 on the upside on Friday, eventually ending the session at $56.74, with a gain of 0.25% or 0.14 points. The heightened volatility saw the trading volume jump to 70,93,479 shares. Company has a market cap of $157,468 M.

Other Hedge Funds, Including , Portland Global Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 25,823 shares of Merck & Co. which is valued at $1,465,197. Merck & Co. makes up approx 0.69% of Portland Global Advisors’s portfolio. Independence Trust Co sold out all of its stake in MRK during the most recent quarter. The investment firm sold 6,451 shares of MRK which is valued $366,030.Carnegie Capital Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 230 additional shares and now holds a total of 26,145 shares of Merck & Co. which is valued at $1,467,780. Merck & Co. makes up approx 0.22% of Carnegie Capital Asset Management’s portfolio. Breton Hill Capital Ltd. sold out all of its stake in MRK during the most recent quarter. The investment firm sold 7,269 shares of MRK which is valued $408,082.Private Asset Management Inc reduced its stake in MRK by selling 18,553 shares or 6.67% in the most recent quarter. The Hedge Fund company now holds 259,690 shares of MRK which is valued at $14,295,935. Merck & Co. makes up approx 2.61% of Private Asset Management Inc’s portfolio.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.